menu

Role of Fetal Fibronectin in Identifying the Risk of Preterm Labor

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Role of Fetal Fibronectin in Identifying the Risk of Preterm Labor

This educational activity covers PTB prevalence and consequences, and the use of diagnostic tests, such as fFN.

Available credits: 0.25

Time to complete: 15 Minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Drs. Eugene Chang and Stephanie Costa will talk about how to better appreciate the prevalence, burden, and consequences of preterm birth and more confidently adopt ACOG and SMFM guidance for use of diagnostic tests, such as fetal fibronectin.  Fetal Fibronectin, or FFN, is a clinical test performed between 22 and 34 weeks completed gestation.  Additionally, they will also discuss how to incorporate appropriate patient disposition strategies into one’s clinical practice when assessing a women’s risk for preterm birth.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:

    Stephanie W. Costa, MD
    Physician at MaternOhio Clinical Associates-Kingsdale Division
    Chair, Department of OB/GYN
    Riverside Methodist Hospital
    Columbus, Ohio

    Dr. Costa has nothing to disclose.

    Eugene Y. Chang, MD
    Associate Professor
    Department of OB/GYN
    Director, Maternal-Fetal Medicine Fellowship
    Medical University of South Carolina, Charleston (MUSC)
    Charleston, SC

    Dr. Chang has received research and consulting fees from Hologic.

    Reviewers/Planners/Authors:

    • Sean T. Barrett, CHCP has nothing to disclose.
    • Andy Beloff has nothing to disclose.
    • David L. Gandell, MD has disclosed that he receives consulting fees from AMAG Pharmaceuticals and is a member of the AMAG Pharmaceuticals and Ducheshay Pharmaceuticals speaker’s bureau.
    • Kia K. Gray, MPH has nothing to disclose.
    • Jessica McGrory has nothing to disclose.
    • Jennifer S. Smith, PhD has nothing to disclose.
    • Ken Brown has nothing to disclose.
  • Target Audience

    The target audience for this activity includes Ob/Gyns, Maternal Fetal Medicine specialists, Obstetric Hospitalists, CNMs, Labor and Delivery nursing staff, and women’s health residents.

  • Learning Objectives

    At the conclusion of this CME activity, participants assessing women for risk of preterm birth will:

    • Better appreciate the prevalence, burden, and consequences of preterm birth.
    • More confidently adopt ACOG and SMFM guidance for use of diagnostic tests, such as fetal fibronectin, when assessing the risk for preterm birth.
    • Incorporate appropriate patient disposition strategies into their clinical practice when assessing a woman’s risk for preterm birth.
  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be available for immediate download at www.reachmd.com.

  • Provider(s)/Educational Partner(s)

    Omnia Education designs educational programs based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

  • Commercial Support

    This activity is supported by an independent educational grant from Hologic.

  • Terms of Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither Prova Education nor Omnia recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Omnia Education or TOPEC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Instructions

    There are no fees for participating in and receiving CME credit for this activity. During the period March 1, 2016, through August 4, 2018, participants must 1) read the learning objectives and faculty disclosures; 2) listen to the full content of the activity and reflect upon its teachings; 3) successfully complete the post-test with a passing score and the evaluation at the end of the activity.

    Participants who successfully complete the activity, post-test and evaluation will have a statement of credit made available immediately.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of ReachMD you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience."

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00

    You must be in to display playlists.

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.